Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07082738 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
A Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,160
- Enrollment target
- 20
- Study locations
NCT07082738: Recruiting Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
NCT07082738 is a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,160 participants, above the 619-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (87% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07082738, a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
Primary Outcome
The annualised moderate or severe COPD exacerbation rate (based on exacerbations reported by the investigator) up to 24 Weeks treatment period compared to placebo
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AZD6793
Study Locations (20)
Florida
- Research Site - Brandon
- Research Site - Cape Coral
- Research Site - Clearwater
- Research Site - Clearwater
- Research Site - Jacksonville
- Research Site - Lake City
- Research Site - Miami
- Research Site - Miami
California
- Research Site - Canoga Park
- Research Site - La Mesa
- Research Site - Los Angeles
- Research Site - Newport Beach
- Research Site - Norco
- Research Site - Tustin
Arizona
- Research Site - Glendale
- Research Site - Phoenix
- Research Site - Phoenix
- Research Site - Phoenix
Alabama
- Research Site - Birmingham
Colorado
- Research Site - Lakewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,160 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2027-11-05 |
| Phase | Phase 2 |
What NCT07082738 shows while recruiting
NCT07082738 is an interventional study that assigns participants to a tested intervention. Its 1,160 participants enrollment target places it among the larger protocols in the corpus, above the 619-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (87% higher).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07082738 names 20 study sites across 5 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07082738 about?
NCT07082738 is a clinical study titled "A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease". This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
What is the current status of trial NCT07082738?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,160 participants. The study started on 2025-06-27. Estimated completion is 2027-11-05.
What conditions does trial NCT07082738 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT07082738?
The interventions under investigation include: Placebo (OTHER), AZD6793 (DRUG).
Who is sponsoring clinical trial NCT07082738?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07082738 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07082738's enrollment target sits among peer trials
1,160 7th of 36 higher than 30 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RECRUITING · Phase 2
-
Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)
COMPLETED · Phase 2
-
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
COMPLETED · Phase 2
-
Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 2
-
Sodium Pyruvate Therapy in COPD Patients
COMPLETED · Phase 2
-
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577599 · 1,160 participants · NA
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
- NCT07237048 · 1,164 participants · Phase 2
Minocycline in Stroke Study at Maimonides
- NCT07009509 · 1,166 participants · NA
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
- NCT04474301 · 1,152 participants
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI